AndroGel Variable Absorption: When to Call Your Doctor

Why AndroGel Absorption Varies So Much

Testosterone topical gel relies on passive diffusion across the stratum corneum, the outermost 10 to 20 micrometers of skin. That thin barrier is not uniform across the body or between patients. The Endocrine Society's 2018 clinical practice guideline notes that transdermal testosterone delivers roughly 10% of the applied dose into circulation, but real-world uptake ranges from about 5% to 15% depending on patient-specific factors [3].

Skin Thickness and Hydration

The stratum corneum on the shoulders contains about 15 cell layers; on the abdomen, that number climbs to 20 or more. Thicker skin slows diffusion. Dry skin also impedes absorption because the gel's hydroalcoholic vehicle relies on moisture in the outer epidermis to support drug partitioning. A 2004 pharmacokinetic study in the Journal of Clinical Endocrinology & Metabolism showed that shifting application from the abdomen to the upper arms increased area under the curve (AUC) by approximately 30% in 1% gel users [2].

Sweat, Sunscreen, and Occlusion

Sweat dilutes the gel film and carries testosterone away before it penetrates. Applying sunscreen, lotions, or emollients within 2 hours of dosing creates an occlusive or competitive layer that can reduce or paradoxically increase absorption depending on the vehicle. The FDA-approved prescribing information for AndroGel 1.62% instructs patients to avoid swimming or showering for at least 2 hours post-application and to avoid applying the product over sunscreen or other topical agents [1].

Hair Follicle Density

Follicular shunts provide a secondary absorption pathway. Body sites with higher follicular density (such as the upper chest) may allow faster initial uptake. A dermatopharmacokinetic analysis published in Pharmaceutical Research demonstrated that follicular penetration accounted for up to 14% of total testosterone permeation through human skin in vitro [4].

Signs That Absorption Is Too Low

Subtherapeutic testosterone levels produce recognizable symptoms. When the gel fails to deliver enough drug, men typically notice the effects within 2 to 4 weeks of starting therapy or after changing application habits.

Persistent Fatigue and Low Libido

Trough total testosterone below 300 ng/dL on a morning blood draw, collected 2 to 4 hours after gel application, is the standard pharmacokinetic signal that absorption is insufficient. Clinically, this manifests as fatigue that does not respond to adequate sleep, reduced sexual desire, and difficulty maintaining erections. The Testosterone Trials (TTrials, N=790), a coordinated set of seven placebo-controlled studies, found that men whose testosterone remained below 300 ng/dL experienced no meaningful improvement in sexual function scores compared with placebo [5].

Worsening Body Composition

Testosterone replacement should slow lean-mass loss and reduce visceral fat. If waist circumference increases or DEXA-measured lean mass declines after 6 months of consistent gel use, inadequate absorption is a common explanation. The TRAVERSE trial (N=5,204) confirmed that testosterone gel users who achieved mid-normal serum levels gained an average of 0.9 kg of lean mass at 12 months versus a 0.37 kg loss in the placebo group [6].

What Lab Values Trigger a Call

Contact your doctor if any of these apply:

• Total testosterone trough <300 ng/dL on two draws at least 1 week apart
• Free testosterone below your lab's reference range when total testosterone is borderline
• Hematocrit rising above 50% on routine CBC, which may indicate that erratic peaks are stimulating erythropoiesis even when troughs are low

Signs That Absorption Is Too High

Over-absorption is less common with gel formulations than with intramuscular injections, but it does occur. Patients who apply the gel to thin-skinned, well-vascularized areas or who occlude the application site with clothing immediately after dosing may push serum testosterone above the physiologic ceiling.

Erythrocytosis and Cardiovascular Warning Signals

The single most concerning consequence of sustained supraphysiologic testosterone is erythrocytosis. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months after starting therapy, and annually thereafter. A hematocrit above 54% requires dose reduction or temporary discontinuation [3]. The TRAVERSE trial, the largest randomized cardiovascular safety study of testosterone to date, reported a major adverse cardiac event (MACE) incidence of 7.0% in the testosterone group versus 7.3% in the placebo group over a mean follow-up of 33 months, establishing non-inferiority but not ruling out risk in subgroups with polycythemia [6].

Mood and Behavioral Changes

Irritability, shortened temper, and sleep fragmentation may appear when testosterone peaks exceed 1,200 ng/dL. These symptoms are not inevitable, but they warrant a dose check. A 2019 analysis of FDA Adverse Event Reporting System (FAERS) data identified aggression and mood swings among the top 10 reported adverse events for testosterone topical products, though reporting bias limits causality claims [7].

Skin Reactions at the Application Site

Persistent erythema, pruritus, or folliculitis at the gel application area may signal local over-concentration or contact sensitization to the hydroalcoholic vehicle. If redness or burning lasts longer than 30 minutes or worsens over successive days, call your prescriber. Switching application sites daily and rotating between shoulders and upper arms can help reduce irritation.

When to Call Your Doctor: A Decision Checklist

Not every fluctuation requires a clinic visit. Use these concrete thresholds to decide.

Call Within 24 Hours

• New breast tenderness or palpable breast tissue (gynecomastia), which signals aromatization of excess testosterone to estradiol
• Sudden leg swelling, warmth, or calf pain, as testosterone therapy carries a small risk of venous thromboembolism (VTE). A 2019 meta-analysis of 9 observational studies (N=349,039) published in Thrombosis Research found an odds ratio of 1.25 (95% CI 1.05 to 1.49) for VTE in testosterone users compared with non-users [8]
• New-onset or suddenly worsening snoring and witnessed apneas, because testosterone can worsen obstructive sleep apnea (OSA)
• Hematocrit above 54% on a routine lab draw
• Chest pressure, palpitations, or shortness of breath at rest

Call at Your Next Scheduled Visit

• Fatigue or low libido persisting beyond 6 weeks of consistent daily application
• Total testosterone trough between 200 and 300 ng/dL on a single draw (repeat the test before changing therapy)
• Acne or oily skin developing after dose titration
• Application-site rash that responds to site rotation but keeps recurring

Call Immediately (Go to an Emergency Department)

• Chest pain radiating to the arm, jaw, or back
• Difficulty breathing or sudden vision changes
• Signs of anaphylaxis (hives, throat tightness, dizziness) after gel application, which is rare but documented in FAERS postmarketing reports [7]

How to Reduce Absorption Variability

Consistent technique is the single biggest lever patients can pull. A 2006 randomized crossover study (N=32) published in Clinical Therapeutics demonstrated that standardized application-site preparation, including washing and thorough drying, reduced the coefficient of variation in serum testosterone AUC by 18% compared with uncontrolled application [9].

Standardize Your Application Routine

Apply the gel at the same time each morning, to the same sites, after showering and fully drying the skin. Do not apply to broken skin or areas with active dermatitis. The FDA label for AndroGel 1.62% specifies the upper arms and shoulders only; the 1% formulation adds the abdomen as a permitted site [1].

Avoid Competing Products

Wait at least 2 hours before applying sunscreen, moisturizer, or deodorant to or near the application site. If you use a topical corticosteroid for eczema or psoriasis, apply it to a different body area or at a different time of day.

Cover the Site After Drying

Once the gel has dried completely (usually 5 to 10 minutes), put on a shirt that covers the application area. This protects household contacts from secondary exposure and creates mild occlusion that may stabilize absorption. The prescribing information states that clothing should cover the site after the gel dries to prevent transfer [1].

Track Your Symptoms

Keep a brief daily log of energy, libido, mood, and sleep quality for the first 8 weeks. Patterns that emerge across days or weeks give your prescriber actionable information. A trough blood draw with simultaneously recorded symptoms is far more useful than a standalone lab value.

Dose Adjustments Your Doctor May Consider

When variable absorption produces unacceptable clinical results, prescribers have several evidence-based options.

Titrate Within the Gel Formulation

AndroGel 1% is dosed at 50, 75, or 100 mg daily. AndroGel 1.62% starts at 40.5 mg and can be titrated to 20.25 mg or up to 81 mg. Dose changes should be guided by trough testosterone drawn 14 days after any adjustment. The prescribing information recommends increasing by one step if the trough is below 350 ng/dL and decreasing by one step if it exceeds 750 ng/dL [1].

Switch Formulation or Route

If absorption remains erratic after optimizing technique and titrating dose, your doctor may recommend testosterone cypionate intramuscular injections (100 to 200 mg every 1 to 2 weeks), nasal testosterone (Natesto, 11 mg per nostril three times daily), or subcutaneous pellets. Each route has its own pharmacokinetic profile, but intramuscular cypionate produces the most predictable trough-to-peak pattern in head-to-head comparisons [3].

Address Underlying Skin Conditions

Eczema, psoriasis, or chronic dry skin at the application site can impair absorption substantially. Treating the underlying dermatologic condition with appropriate non-competing therapies, such as a nighttime emollient applied 10 to 12 hours before the gel, may restore consistent uptake.

Monitoring Schedule After a Dose Change

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's testosterone therapy guideline, has stated: "The first follow-up lab after a dose adjustment should occur at 2 to 4 weeks, measured 2 to 4 hours after gel application. Waiting longer risks prolonged exposure to subtherapeutic or supraphysiologic levels" [3].

The Endocrine Society recommends the following monitoring cadence for men on testosterone topical therapy:

| Timepoint | Labs | Clinical Check | |---|---|---| | Baseline | Total T, free T, CBC, PSA, lipids, LFTs | Symptoms, DRE if age ≥40 | | 1 month | Total T (trough, 2-4 h post-application) | Symptom review | | 3 months | Total T, CBC (hematocrit) | Application-site exam | | 6 months | Total T, free T, CBC, PSA | Bone density if indicated | | 12 months and annually | Total T, free T, CBC, PSA, lipids | Full clinical review |

A second guideline-level recommendation from the American Urological Association (AUA, 2018) states: "Serum testosterone should be measured midway between injections for IM formulations and 2 to 4 hours after application for transdermal formulations to ensure the patient is within the therapeutic range of 450 to 600 ng/dL" [10].

Secondary Exposure: A Specific Absorption Risk for Household Contacts

Variable absorption does not only affect the patient. The FDA issued a boxed warning on all testosterone topical products after postmarketing reports documented virilization in children exposed to unwashed skin or contaminated bed linens [1]. Signs of secondary exposure in children include premature pubic hair, genital enlargement, increased acne, and aggressive behavior. In women, exposure can cause acne, hirsutism, and menstrual irregularity. If any household contact develops these symptoms, seek medical attention and wash all potentially contaminated fabrics in hot water.

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for testosterone gels requires that patients receive a Medication Guide at each dispensing, and prescribers must counsel patients on handwashing, site coverage, and shower-before-contact protocols [1].

What the Data Show About Long-Term Outcomes on Topical Testosterone

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, is the most definitive cardiovascular safety study of testosterone gel to date. Over a mean 33-month follow-up, the incidence of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) was 7.0% in the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.78 to 1.17), meeting the prespecified non-inferiority margin [6]. Hematocrit exceeded 54% in 2.6% of testosterone-treated men versus 0.1% of placebo-treated men, reinforcing the importance of CBC monitoring.

A secondary analysis of TRAVERSE published in JAMA in 2024 found no increase in prostate cancer incidence over 4 years (HR 0.97; 95% CI 0.51 to 1.84), addressing a longstanding concern [11]. PSA monitoring remains standard practice, but the data no longer support withholding testosterone from men with low cancer risk based on prostate fears alone.